Medicon Village

Medicon Village Investor Panel (MVIP) returns for 2026 and is now open for applications

Published by  
Medicon Village

Building on a remarkable debut edition that drew together some of the Nordic region’s most influential life science investors, Medicon Village is proud to announce the return of the Medicon Village Investor Panel for the 2026 edition.

Following a strong first edition in 2025, the Medicon Village Investor Panel (MVIP) returns for a second edition in 2026. The initiative continues to connect life science companies with an experienced international investor panel through a structured format focused on investment readiness. Organised by Medicon Village and led by Markus Neuding, corporate finance expert and owner of Sedermera Corporate Finance, MVIP is characterised by its long-term orientation. It is designed as a recurring platform that enables companies to refine their investment propositions, build lasting relationships with investors, and develop the strategic maturity required for complex funding processes.

“MVIP reflects our role at Medicon Village as a meeting place where companies and investors can engage in meaningful dialogue. The first edition demonstrated the value of creating a structured setting for this type of interaction,” says Sarah Lidé, Deputy CEO of Medicon Village Innovation.

The 2025 edition brought together eight companies across pharma, biotech, medtech, diagnostics and digital health, who presented to a panel of Nordic investors. The format enabled in-depth dialogue and direct feedback, with participating companies strengthening their investment cases and establishing new investor relationships. Feedback from both companies and investors was consistently positive, with companies highlighting the opportunity for high-quality, in-depth discussions as well as actionable feedback to support their funding strategies in both the short and long term.

“Drawing on my experience in corporate finance and as an active investor, I see clear value in initiatives like MVIP. It connects investors with promising companies and provides entrepreneurs with relevant feedback and visibility,” says Markus Neuding.

The concept has attracted strong interest from venture capital firms, family offices and individual investors who recognise Medicon Village’s position as a leading life science ecosystem with a strong community and a track record of high-quality science. For the 2026 edition, Medicon Village is assembling another distinguished panel of national and international investors including Linc AB, J.P. Morgan, Curie.Bio, Hadean Ventures, HealthCap and Innovestor. Jonathan Gertler of Back Bay Life Science Advisors will also join the committee, bringing extensive experience from advising Nordic life science companies. Additional investors will be announced in the coming weeks.

“By creating a structured, recurring dialogue between entrepreneurs and leading capital, we are strengthening investment readiness within the Medicon Village community,” says Francesco Bez, Innovation Manager at Medicon Village Innovation.

Applications for the 2026 edition are now open

Applications for the 2026 edition are now open. MVIP is open to life science companies within and beyond the Medicon Village ecosystem. Member companies will be prioritised in the selection process, and those admitted to the programme will participate free of charge. Non-member companies are welcome to apply under the same eligibility criteria and will be subject to an entry fee of SEK 49,000 (excluding VAT) upon acceptance.

Companies are encouraged to apply in good time, as places are limited and applications will be evaluated on a rolling basis. The application deadline is 11 May 2026.

APPLICATION LINK

For further information, please feel free to contact: